Novavax reported $162.58M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Adma Biologics USD 237.88M 457K Dec/2025
Agenus USD 35.32M 2.51M Dec/2025
AstraZeneca USD 1.55B 73K Mar/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
Cassava Sciences USD 48.31M 0 Dec/2025
Geron USD 640.9M 2.54M Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
MannKind USD 308.91M 1.07M Mar/2026
Merck USD 2.47B 12.72M Dec/2025
Minerva Neurosciences USD 1000 0 Sep/2024
Moderna USD 391M 2M Sep/2025
Novartis USD 1.91B 10.64M Dec/2025
Novavax USD 162.58M 106K Dec/2025
Pfizer USD 5.7B 13M Mar/2026
Sanofi EUR 1.21B 8.25M Mar/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
TG Therapeutics USD 155.31M 95K Dec/2025